Abstract
In 2014, India’s Laurus Laboratories acquired simulated moving bed (SMB) technology, a $5 million investment in its generic pharmaceutical chemicals business. Although not a huge sum to pay for the chiral separations equipment, which is commonly used in the U.S. and Europe, it was a risky move in India, a region known for low-cost, basic chemistry services. But it paid off. Today, Laurus may be the only company of its kind in India doing SMB separations. The SMB investment was one of many for a firm that has grown over the past 10 years from a small R&D contractor to one of India’s most successful pharmaceutical contract development and manufacturing organizations. It is also indicative of the firm’s commitment to high-end pharmaceutical chemistry. Last year, Laurus struck a deal to manufacture sofosbuvir, the key active pharmaceutical ingredient (API) in Gilead Sciences’ hepatitis C drugs, for marketing in developing countries. Laurus
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
